Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
出版年份 2014 全文链接
标题
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
作者
关键词
-
出版物
PLoS One
Volume 9, Issue 8, Pages e105638
出版商
Public Library of Science (PLoS)
发表日期
2014-08-29
DOI
10.1371/journal.pone.0105638
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
- (2013) Guntram Schernthaner et al. DIABETES CARE
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- (2013) J. P. H. Wilding et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
- (2013) David Polidori et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
- (2013) Damayanthi Devineni et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
- (2012) D. Devineni et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
- (2011) S. Sha et al. DIABETES OBESITY & METABOLISM
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
- From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
- (2009) Harold Bays CURRENT MEDICAL RESEARCH AND OPINION
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
- (2009) J. E. Gerich DIABETIC MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search